Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tratamiento integral individualizado para el carcinoma hepatocelular avanzado (ICT-HCC)

28 de septiembre de 2026 actualizado por: Nanjing Tianyinshan Hospital

Estudio de cohorte exploratorio e investigación mecanicista sobre tratamiento integral individualizado después del tratamiento estándar para el carcinoma hepatocelular avanzado

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

270

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210000
        • Reclutamiento
        • China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥18 years old, male or female
  2. Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with radical treatment (radical surgery, ablation, radiotherapy, etc.)
  3. Clinical disease progression after first-line targeted combined immune system therapy (PD-1 or PD-L1 monoclonal antibody only)
  4. Life expectancy exceeds 3 months
  5. ECOG physical condition score 0~1
  6. Women of childbearing age must have a serum pregnancy study done within 7 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must consent to contraception within 24 weeks from the date of signing the informed consent to the last administration of the study drug
  7. Before the first dose of the investigational drug, the laboratory test values met the following conditions: ①blood routine (no blood transfusion within 14 days before screening, no hematopoietic stimulating drug correction) : white blood cell count (WBC) ≥ 2.0 × 109/L; platelet (PLT) ≥ 60× 109/L; hemoglobin content (HGB) ≥ 8.0 g/dL; ② Liver function: aspartate transferase (AST) ≤ 2.5x ULN; alanine aminotransferase (ALT) ≤ 2.5 x ULN; Serum total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert syndrome total bilirubin ≤ 3.0 mg/dL); ③ Renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance rate (CrCl) ≥ 50 mL/minute; ④ Coagulation function: international normalized ratio (INR) ≤ 1.5 x ULN, activated partial thromboplastin time (APTT) ≤ 1.5 x ULN (only for patients who are not currently receiving anticoagulant therapy, patients who are currently receiving anticoagulant therapy should receive a steady dose of anticoagulant therapy)
  8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up

Exclusion Criteria:

  1. Pathological types of other non-hepatocellular carcinomas, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc. previously confirmed by histology/cytology
  2. Child-Pugh grade of liver function> 7 points
  3. Major cardiovascular impairment in the 6 months prior to initial administration of the drug, such as a New York Heart Association (NYHA) Class II or higher history of congestive heart failure, unstable angina, myocardial infarction or stroke, or arrhythmia associated with hemodynamic instability; Corrected QT (QTc) interval lengthening >480ms
  4. Other malignancies developed ≤ 5 years before the first dose, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery (hormone therapy for non-metastatic prostate cancer or breast cancer is allowed)
  5. Have had an active autoimmune disease in the past 2 years that requires systemic treatment, including but not limited to autoimmune hepatitis, lupus erythematosus, etc
  6. Uncontrolled active infection, such as active tuberculosis, HIV infection, etc.; Patients with HBV-DNA replication level below 10000IU/mL and continuous oral antiviral therapy could be enrolled.
  7. Had undergone major surgery in the 28 days prior to randomization or planned to undergo major surgery during the study period
  8. Use of live attenuated vaccine within 28 days prior to randomization, or anticipated use of such live attenuated vaccine during the study period (patients are not allowed to receive live attenuated influenza vaccine 4 weeks prior to randomization, during treatment, and within 5 months after the final administration of adbelizumab)
  9. Received any other investigational drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF
  10. Use of corticosteroids (> 10 mg/ day prednisone or equivalent dose) or other immunosuppressants within ≤ 14 days prior to the first dose of the study drug. Allowing inhaled or topical use of steroids and adrenal replacement steroids in the absence of active autoimmune disease; Patients received systemic immunosuppressive drugs (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] drugs) within 1 week prior to randomization. Patients receiving short-term, systemic immunosuppressant therapy, such as glucocorticoids for nausea, vomiting, or anaphylaxis management or prevention, may be enrolled in the study after investigator review. To allow the use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease, corticosteroids such as fluhydrocortisone in patients with postural hypotension, and low-dose glucocorticoid supplements for adrenal insufficiency; Known mental illness, alcoholism, inability to quit smoking, drug or substance abuse
  11. In the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study, such as non-compliance with the protocol, other serious illnesses (including mental illness) requiring combined treatment, serious laboratory abnormalities, family or social factors that may affect the safety of the subjects, or the collection of data and samples

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm 1

XELOX/FOLFOX4+ Adebelizumab + Apatinib+Icaritin

FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles

Adebrelimab 1200mg, intravenous infusion, every 3 weeks

Experimental: Arm 2

Adebelizumab + Apatinib+Icaritin

Adebrelimab 1200mg, intravenous infusion, every 3 weeks

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Experimental: Arm 3a

QL1706+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimental: Arm 3b

Retlirafusp alfa+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimental: Arm 4

The original targeted combination immunotherapy+HAIC

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Hepatic Arterial Infusion Chemotherapy

Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.

Experimental: Arm 5a

QL1706+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimental: Arm 5b

Retlirafusp alfa+ Apatinib+Icaritin

Apatinib 250mg, oral, once daily.

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Experimental: Arm 6a

QL1706+Bevacizumab+Icaritin

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

Experimental: Arm 6b

Retlirafusp alfa+Bevacizumab+Icaritin

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
PFS(Progression-free Survival)
Periodo de tiempo: 24 months

Progression-free survival (PFS) was defined as the time from treatment initiation on Day 1 to the earliest occurrence of radiologically confirmed disease progression, as assessed by tumor imaging, or death from any cause, whichever came first. Evaluations were conducted by the investigator in accordance with RECIST v1.1.

24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
OS(Overall survival)
Periodo de tiempo: 48 months

Overall survival (OS) was defined as the duration from treatment initiation on Day 1 to death from any cause.

48 months
ORR(Objective response rate)
Periodo de tiempo: 24 months

Objective response rate (ORR) was defined as the proportion of subjects achieving a complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1.

24 months
DCR(Disease control rate )
Periodo de tiempo: 24 months

Disease control rate (DCR) was defined as the proportion of subjects achieving a complete response (CR), partial response (PR), or stable disease (SD) lasting ≥8 weeks, as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1.

24 months
DOR(Duration of Response)
Periodo de tiempo: 24 months

Duration of response (DOR) was defined as the time from the first documented objective response (CR or PR) to the earliest occurrence of radiological disease progression or death from any cause, whichever occurred first. Both response and progression were evaluated by the investigator according to RECIST v1.1.

24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de mayo de 2025

Finalización primaria (Estimado)

15 de diciembre de 2027

Finalización del estudio (Estimado)

15 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

27 de febrero de 2025

Primero enviado que cumplió con los criterios de control de calidad

23 de marzo de 2025

Publicado por primera vez (Actual)

25 de marzo de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Última verificación

1 de marzo de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir